Variations in serum alkaline DNase activity: a possible clinical test for therapeutic prognosis of human tumors.
(1986) Anticancer Research : international journal of cancer research and treatment — Vol. 6, n° 5, p. 949-956 (1986)
Files
No attached file found for this publication.
Details
- Authors
- Abstract
- Previously published histochemical observations indicated that variations in serum alkaline DNase activity (SADA) could be considered as a possible prognostic test for human tumor therapy. In more than 80 cancer patients biochemical measurements of SADA were performed using the spectrophotometrical technique. A decrease of SADA promptly after the beginning of tumor treatment (phase I) may be interpreted as an early sign of therapeutically induced tumor necrosis and as a positive response to the treatment. A delayed regain of SADA (phase II) can predict the long term evolution of the disease. In this phase (II), a regain of SADA up to values higher than the initial value corresponds to a complete tumor regression. If the regain is limited to values lower than the initial value, only a partial tumor regression is seen. No variations of SADA were observed in patients without therapeutic response and with fatal evolution.
- Affiliations
Citations
Taper, H., Lans, M., Economidou-Karaoglou, A., de Gerlache, J., & Roberfroid, M. (1986). Variations in serum alkaline DNase activity: a possible clinical test for therapeutic prognosis of human tumors. Anticancer Research : international journal of cancer research and treatment, 6(5), 949-956. https://hdl.handle.net/2078.5/135393 (Original work published 1986)